Moxonidine
Modify Date: 2024-01-02 08:53:50
Moxonidine structure
|
Common Name | Moxonidine | ||
|---|---|---|---|---|
| CAS Number | 75438-57-2 | Molecular Weight | 241.678 | |
| Density | 1.5±0.1 g/cm3 | Boiling Point | 364.7±52.0 °C at 760 mmHg | |
| Molecular Formula | C9H12ClN5O | Melting Point | 40-43 °C(lit.) | |
| MSDS | USA | Flash Point | 174.3±30.7 °C | |
Use of MoxonidineMoxonidine(BDF5895) is a selective agonist at the imidazoline receptor subtype 1, used as antihypertensive agent.Target: I1-RMoxonidine is a centrally acting antihypertensive agent. Mixed Nischarin (I1 imidazoline receptor) and α2-AR (adrenergic) agonist; displays 40-fold higher affinity for I1 receptors versus α2-adrenoceptors. Moxonidine reduced stimulated NE overflow (log EC50: -6.15 +/- 0.14). AGN192403, a selective ligand at I1-R, had no influence on the dose-response curve of moxonidine (log EC50: -6.01 +/- 0.25) [1]. The hypotensive and bradycardic actions of moxonidine but not clonidine are mediated through imidazoline receptors and are dependent on intact noradrenergic pathways within the RVLM. Furthermore, the noradrenergic innervation may be associated with a 42 kDa imidazoline receptor protein [2]. |
| Name | 4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methylpyrimidin-5-amine |
|---|---|
| Synonym | More Synonyms |
| Description | Moxonidine(BDF5895) is a selective agonist at the imidazoline receptor subtype 1, used as antihypertensive agent.Target: I1-RMoxonidine is a centrally acting antihypertensive agent. Mixed Nischarin (I1 imidazoline receptor) and α2-AR (adrenergic) agonist; displays 40-fold higher affinity for I1 receptors versus α2-adrenoceptors. Moxonidine reduced stimulated NE overflow (log EC50: -6.15 +/- 0.14). AGN192403, a selective ligand at I1-R, had no influence on the dose-response curve of moxonidine (log EC50: -6.01 +/- 0.25) [1]. The hypotensive and bradycardic actions of moxonidine but not clonidine are mediated through imidazoline receptors and are dependent on intact noradrenergic pathways within the RVLM. Furthermore, the noradrenergic innervation may be associated with a 42 kDa imidazoline receptor protein [2]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.5±0.1 g/cm3 |
|---|---|
| Boiling Point | 364.7±52.0 °C at 760 mmHg |
| Melting Point | 40-43 °C(lit.) |
| Molecular Formula | C9H12ClN5O |
| Molecular Weight | 241.678 |
| Flash Point | 174.3±30.7 °C |
| Exact Mass | 241.073044 |
| PSA | 71.43000 |
| LogP | 0.84 |
| Vapour Pressure | 0.0±0.8 mmHg at 25°C |
| Index of Refraction | 1.681 |
| Storage condition | Desiccate at +4°C |
| Hazard Codes | Xn |
|---|---|
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |
| RTECS | UV6260290 |
| Hazard Class | 6.1 |
CAS#:75438-54-9
CAS#:67-56-1
CAS#:287099-40-5
CAS#:124-41-4![1-[1-((4,6-dichloro-2-methyl-pyrimidin-5-yl)imino)-ethyl]-imidazolidin-2-one Structure](https://www.chemsrc.com/caspic/129/438000-58-9.png)
CAS#:438000-58-9|
Selective imidazoline agonist moxonidine plus the ACE inhibitor ramipril in hypertensive patients with impaired insulin sensitivity: partners in a successful MARRIAGE?
Curr. Med. Res. Opin. 20(3) , 359-67, (2004) Hypertension in combination with clinically overt diabetes mellitus is recognized as a particularly powerful combination of risk factors that greatly increases cardiovascular vulnerability. There is a... |
|
|
Moxonidine: a review of safety and tolerability after seven years of clinical experience.
J. Hypertens. 17 , S37-S39, (1999) Centrally acting antihypertensive drugs, or sympatholytics, (reserpine, methyldopa and clonidine) have a long history of efficacy but are now little used in most countries. One of the most important r... |
|
|
[The efficacy of antihypertension drugs and their combinations in the non-treated hypertension].
Med. Tr. Prom. Ekol. (5) , 7-11, (2013) In case of non-treated hypertension several medications and their combinations were studied (captopril, and moxonidine as such, captopril + nifedipine, captopril + moxonidine). Moxonidine to be more e... |
| 4-chloro-5-(imidazoline-2-ylamino)-6-methoxy-2-methylpyrimidine |
| [3H]-Moxonidine |
| 4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methylpyrimidin-5-amine |
| 4-Chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methyl-5-pyrimidinamine |
| Norcynt |
| 4-Chloro-N-(imidazolidin-2-ylidene)-6-methoxy-2-methylpyrimidin-5-amine |
| BE 5895 |
| 5-Pyrimidinamine, 4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methyl- |
| Normoxocin |
| Lomox |
| 4-chloro-N-(4,5-dihydro-1H9imidazol-yl)-6-methoxy-2-methyl-5-pyrimidinamine |
| Physiotens |
| [14C]-Moxonidine |
| 4-chloro-5-[(4,5-dihydro-1H-imidazol-2-yl)-amino]-6-methoxy-2-methylpyrimidine |
| T6N CNJ B1 DO1 FG EM- BT5M CN BUTJ |
| Nucynt |
| Cynt |
| Moxonidinum [Latin] |
| Moxonidine |
| T6N CNJ B1 DO1 FG ENU- BT5MYMTJ |
| MFCD06795643 |